AIDSPub Date : 2025-02-01Epub Date: 2024-09-27DOI: 10.1097/QAD.0000000000004028
Daniele Pastori, Francesco Del Sole, Tommaso Brogi, Maria Del Ben, Caterina Fimiani, Claudio Maria Mastroianni, Ivano Mezzaroma
{"title":"Epicardial fat and liver stiffness by acoustic radiation force impulse elastography in people with HIV-1 infection without liver disease.","authors":"Daniele Pastori, Francesco Del Sole, Tommaso Brogi, Maria Del Ben, Caterina Fimiani, Claudio Maria Mastroianni, Ivano Mezzaroma","doi":"10.1097/QAD.0000000000004028","DOIUrl":"10.1097/QAD.0000000000004028","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between increased epicardial fat thickness (EFT) and liver stiffness measurement (LSM), as assessed by elastography in people with human immunodeficiency virus type 1 (HIV-1) infection (PWH).</p><p><strong>Methods: </strong>Ninety-one PWH on effective antiretroviral treatment (ART) were enrolled. EFT was measured by transthoracic echocardiography. Liver steatosis was evaluated by ultrasound Hamaguchi criteria and LSM by elastography with acoustic radiation force impulse (ARFI) technique. LSM ≥8 kPa was suggestive of clinically relevant fibrosis.</p><p><strong>Results: </strong>Mean age was 54.3 years and 27.5% were women. EFT correlated with HIV-1 infection duration (rS 0.252, P = 0.016), age at study entry (rS 0.527, P < 0.001), BMI (rS 0.363, P < 0.001), waist circumference (rS 0.549, P < 0.001), HDL (rS -0.391, P < 0.001), triglycerides (rS 0.375, P < 0.001), Hamaguchi score (rS 0.279, P = 0.007), right lobe of the liver (rS 0.259, P = 0.014), left ventricular mass/body surface area (rS 0.220, P = 0.036).A LSM ≥8 kPa was found in 20.9% of PWH, more commonly in those with EFT above the median >5.6 mm (30.4% vs. 11.1%, P = 0.038). LSM significantly correlated with EFT (rS 0.274, P = 0.009), CD4 + cells (rS -0.320, P = 0.003) and nadir of CD4 + cells (rS -0.292, P = 0.007).In a subgroup ( n = 53), a homeostasis model assessment of insulin resistance (HOMA-IR) index >2.33 identified increased EFT, [area under the curve (AUC) 0.73, 95% confidence interval (CI) 0.59-0.84, P = 0.001) while an HOMA-IR >3.27 predicted increased LSM (AUC 0.76, 95% CI 0.62-0.87, P = 0.005).</p><p><strong>Conclusions: </strong>PWH with increased EFT have worse metabolic profile and a high proportion of clinically relevant fibrosis at ARFI elastography, despite normal liver function tests. The HOMA-IR index might be used to identify PWH with increased EFT and liver fibrosis.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"115-122"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-11-28DOI: 10.1097/QAD.0000000000004078
Iulia Filip
{"title":"Strategies for managing weight gain associated with antiretroviral therapy: switch or add?","authors":"Iulia Filip","doi":"10.1097/QAD.0000000000004078","DOIUrl":"10.1097/QAD.0000000000004078","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"N3-N5"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2025-01-02DOI: 10.1097/QAD.0000000000004058
Francisco González-Scarano, Dennis L Kolson
{"title":"Imaging brain inflammation in virally suppressed people with HIV-1.","authors":"Francisco González-Scarano, Dennis L Kolson","doi":"10.1097/QAD.0000000000004058","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004058","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"39 2","pages":"204-205"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-10-10DOI: 10.1097/QAD.0000000000004038
Tom Sumner, Rebecca A Clark, Tomos O Prys-Jones, Roel Bakker, Gavin Churchyard, Richard G White
{"title":"The potential impact of new tuberculosis vaccines on the burden of tuberculosis in people with HIV in South Africa.","authors":"Tom Sumner, Rebecca A Clark, Tomos O Prys-Jones, Roel Bakker, Gavin Churchyard, Richard G White","doi":"10.1097/QAD.0000000000004038","DOIUrl":"10.1097/QAD.0000000000004038","url":null,"abstract":"<p><strong>Background: </strong>People with HIV (PWH) are at an increased risk of tuberculosis (TB). New TB vaccines may help reduce this burden. New TB vaccine candidates are well tolerated and immunogenic in PWH. There are currently limited data on vaccine efficacy in this population.</p><p><strong>Methods: </strong>Using mathematical modeling, we explored the potential impact of a novel TB vaccine on TB burden in PWH in South Africa between 2030 and 2050. We compared the impact of a vaccine delivered irrespective of HIV status to vaccination of either PWH or people without HIV. We explored the impact of reduced vaccine efficacy and duration of protection in PWH relative to people without HIV on our model predictions.</p><p><strong>Results: </strong>Vaccination irrespective of HIV status, with a vaccine with equal efficacy and duration in PWH, could avert up to 1.01 (95% range: 0.96-1.22) million TB cases in PWH. Restricting vaccination to PWH or people without HIV would achieve 65% (60-70) and 48% (46-53) of the total impact, respectively. These results are strongly dependent on the assumed efficacy and duration of protection in PWH. Further information on these characteristics is important to identify the most efficient use of new vaccines to reduce TB burden in PWH.</p><p><strong>Conclusion: </strong>Our results suggest that new vaccines could play an important role in reducing the TB burden in PWH. Vaccines targeted at people without HIV could provide significant indirect benefit to PWH, but vaccines which are well tolerated and effective in PWH will be critical to maximizing the impact in this population.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"175-183"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Amebic liver abscess presenting in a nonendemic region after a 12-year latency in a patient with well controlled HIV infection.","authors":"Alejandro Díez-Vidal, Sofía Gil-Garrote, Beatriz Díaz-Pollán, Graciela Rodríguez-Sevilla, Patricia Martínez-Martín, Cristina Marcelo-Calvo, Marta Díaz-Menéndez","doi":"10.1097/QAD.0000000000004070","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004070","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"39 2","pages":"211-213"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-10-15DOI: 10.1097/QAD.0000000000004032
Molly Hey, Lucy Thompson, Clara Portwood, Harriet Sexton, Mary Kumarendran, Zoe Brandon, Shona Kirtley, Joris Hemelaar
{"title":"Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV.","authors":"Molly Hey, Lucy Thompson, Clara Portwood, Harriet Sexton, Mary Kumarendran, Zoe Brandon, Shona Kirtley, Joris Hemelaar","doi":"10.1097/QAD.0000000000004032","DOIUrl":"10.1097/QAD.0000000000004032","url":null,"abstract":"<p><strong>Objective: </strong>Women with HIV (WHIV) are at an increased risk of adverse perinatal outcomes compared to women without HIV, despite antiretroviral therapy (ART). There is evidence that the risk of adverse perinatal outcomes may differ according to ART regimen. We aimed to assess the risk of adverse perinatal outcomes among WHIV receiving different classes of ART, compared to women without HIV.</p><p><strong>Design: </strong>A systematic review and meta-analysis.</p><p><strong>Methods: </strong>We searched Medline, CINAHL, Global Health, and EMBASE for studies published between January 1, 1980, and July 14, 2023. We included studies which assessed the risk of 11 predefined adverse perinatal outcomes among WHIV receiving nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, protease inhibitor based ART or integrase strand transfer inhibitor (INSTI)-based ART, compared to women without HIV. The perinatal outcomes assessed were preterm birth (PTB), very PTB (VPTB), spontaneous PTB (sPTB), low birthweight (LBW), very LBW (VLBW), term LBW, preterm LBW, small for gestational age (SGA), very SGA (VSGA), stillbirth and neonatal death (NND). Random effects meta-analyses examined the risk of each adverse outcome in WHIV receiving NNRTI-based, protease inhibitor based, or INSTI-based ART, compared with women without HIV. Subgroup and sensitivity analyses were conducted based on country income status, study quality, and timing of ART initiation. The protocol is registered with PROSPERO, CRD42021248987.</p><p><strong>Results: </strong>Of 108 720 identified citations, 22 cohort studies including 191 857 women were eligible for analysis. We found that WHIV receiving NNRTI-based ART (mainly efavirenz or nevirapine) are at an increased risk of PTB (risk ratio 1.40, 95% confidence interval 1.27-1.56), VPTB (1.94, 1.25-3.01), LBW (1.63, 1.30-2.04), SGA (1.53, 1.17-1.99), and VSGA (1.48, 1.16-1.87), compared with women without HIV. WHIV receiving protease inhibitor based ART (mainly lopinavir/ritonavir or unspecified) are at an increased risk of PTB (1.88, 1.55-2.28), VPTB (2.06, 1.01-4.18), sPTB (16.96, 1.01-284.08), LBW (2.90, 2.41-3.50), VLBW (4.35, 2.67-7.09), and VSGA (2.37, 1.84-3.05), compared with women without HIV. WHIV receiving INSTI-based ART (mainly dolutegravir) are at an increased risk of PTB (1.17, 1.06-1.30) and SGA (1.20, 1.08-1.33), compared with women without HIV.</p><p><strong>Conclusion: </strong>The risks of adverse perinatal outcomes are higher among WHIV receiving ART compared with women without HIV, irrespective of the class of ART drugs. This underlines the need to further optimize ART in pregnancy and improve perinatal outcomes of WHIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"162-174"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-10-10DOI: 10.1097/QAD.0000000000004034
Leah H Rubin, Pauline M Maki, Yong Du, Shannon Eileen Sweeney, Riley O'Toole, Hwanhee Nam, Hannah Lee, Ana R Soule, Steven P Rowe, Wojciech G Lesniak, Il Minn, Raha Dastgheyb, Eran F Shorer, Katrina A Wugalter, Joan Severson, Yunkou Wu, Andrew W Hall, William B Mathews, Michael Kassiou, Robert F Dannals, Seble G Kassaye, Todd T Brown, Arnold Bakker, Martin G Pomper, Jennifer M Coughlin
{"title":"Imaging the translocator protein 18 kDa within cognitive control and declarative memory circuits in virally suppressed people with HIV.","authors":"Leah H Rubin, Pauline M Maki, Yong Du, Shannon Eileen Sweeney, Riley O'Toole, Hwanhee Nam, Hannah Lee, Ana R Soule, Steven P Rowe, Wojciech G Lesniak, Il Minn, Raha Dastgheyb, Eran F Shorer, Katrina A Wugalter, Joan Severson, Yunkou Wu, Andrew W Hall, William B Mathews, Michael Kassiou, Robert F Dannals, Seble G Kassaye, Todd T Brown, Arnold Bakker, Martin G Pomper, Jennifer M Coughlin","doi":"10.1097/QAD.0000000000004034","DOIUrl":"10.1097/QAD.0000000000004034","url":null,"abstract":"<p><strong>Objectives: </strong>Virally suppressed people with HIV (VS-PWH) show heterogeneity in patterns of cognitive dysfunction. To better understand the relationship between the neuroimmune response and cognition, we used PET to image the translocator protein 18 kDa (TSPO). The study examined HIV-serostatus differences in TSPO as well as associations between regional TSPO and select cognitive processes defined using the Research Domain Criteria (RDoC) framework.</p><p><strong>Design: </strong>Cross-sectional investigation in VS-PWH ( n = 25) versus HIV-uninfected individuals ( n = 18) of cognitive control and declarative memory, as well as [ 11 C]DPA-713 PET measures of TSPO within cognitive control and declarative memory regions of interest (ROI).</p><p><strong>Methods: </strong>Group differences in [ 11 C]DPA-713 binding ( VT ) in cognitive control or declarative memory regions were examined using linear mixed models. Tests of associations between factor-derived cognitive system measures and PET measures were performed, controlling for TSPO genotype.</p><p><strong>Results: </strong>There were no group differences in any of the four factor-derived cognitive system measures. VS-PWH had higher log [ 11 C]DPA-713 VT across cognitive control regions [unstandardized beta coefficient reflecting mean difference [ B ] = 0.23, SE = 0.11, 95% confidence interval (CI) 0.01-0.45, P = 0.04] and declarative memory regions ( B = 0.24, SE = 0.11, 95% CI 0.02-0.45, P = 0.03). Higher log [ 11 C]DPA-713 VT in cognitive control regions related to poorer cognitive control in each group, and to worse self-reported cognitive performance in VS-PWH. Log [ 11 C]DPA-713 VT in each declarative memory region did not associate with measured declarative memory.</p><p><strong>Conclusion: </strong>A localized neuroimmune response marked by high TSPO in brain regions that subserve cognitive control may contribute to poorer cognitive control in VS-PWH.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"133-142"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-10-08DOI: 10.1097/QAD.0000000000004029
Renee Heffron, Timothy R Muwonge, Katherine K Thomas, Kidist Zewdie, Timothy Ssebuliba, Gabrielle Stein, Susan Morrison, Josephine Badaru, Agnes Nakyanzi, Felix Bambia, Kenneth Mugwanya, Christina Wyatt, Flavia Matovu, Michael T Yin, Andrew Mujugira
{"title":"Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesterone acetate contraception.","authors":"Renee Heffron, Timothy R Muwonge, Katherine K Thomas, Kidist Zewdie, Timothy Ssebuliba, Gabrielle Stein, Susan Morrison, Josephine Badaru, Agnes Nakyanzi, Felix Bambia, Kenneth Mugwanya, Christina Wyatt, Flavia Matovu, Michael T Yin, Andrew Mujugira","doi":"10.1097/QAD.0000000000004029","DOIUrl":"10.1097/QAD.0000000000004029","url":null,"abstract":"<p><strong>Background: </strong>Injectable depot medroxyprogesterone acetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV preexposure prophylaxis (PrEP) may be offered. For young women who choose to use both agents concurrently, it is unknown whether they will experience declines in bone mineral density (BMD) beyond those elicited by either product singly.</p><p><strong>Methods: </strong>From 2018 to 2022, we conducted a 2-year prospective study with women ages 16-25 years in Kampala, Uganda desiring pregnancy and HIV prevention. Women were provided condoms, injectable DMPA, and/or FTC/TDF, according to their choices and underwent annual dual X-ray absorptiometry (DXA) scans. We used tenofovir-diphosphate (TFV-DP) quantification in dried blood spots and DMPA injection dates to classify exposure. Linear regression models estimated the difference in percent BMD change from baseline to month 12 for women using FTC/TDF and DMPA versus women using neither product.</p><p><strong>Results: </strong>Of 499 enrolled women, discontinuation and re-starting of contraception and PrEP was common. Women consistently using neither product ( n = 39) experienced BMD increases. Women with consistent use of both products during 1 year ( n = 22) experienced an average BMD loss of 1.04% at lumbar spine and hip and 1.77% at femoral neck. These losses were different relative to women who used neither agent: lumbar spine -3.35% (95% CI -5.13 to -1.56%, P = 0.001), total hip -2.24% (95% CI -3.87 to -0.60%, P = 0.009), and femoral neck -1.71% (95% CI -3.73 to 0.31%, P = 0.102).</p><p><strong>Conclusion: </strong>We observed a trend for women with concurrent DMPA and FTC/TDF PrEP use to have 1-3% lower BMD than unexposed women after 12 months.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"123-132"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2025-01-02DOI: 10.1097/QAD.0000000000004064
Christina Wiesmann, Brian Conway
{"title":"The challenge of normalizing vaccine behaviors in the postpandemic era.","authors":"Christina Wiesmann, Brian Conway","doi":"10.1097/QAD.0000000000004064","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004064","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"39 2","pages":"206-207"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2025-02-01Epub Date: 2024-10-24DOI: 10.1097/QAD.0000000000004045
Lelia H Chaisson, Betina Durovni, Nasir Umar, Silvia Cohn, Lawrence H Moulton, Eileen Scully, Solange Cavalcante, Jonathan E Golub, Richard E Chaisson, Valeria Saraceni
{"title":"Sex differences in tuberculosis infection and disease among people with HIV.","authors":"Lelia H Chaisson, Betina Durovni, Nasir Umar, Silvia Cohn, Lawrence H Moulton, Eileen Scully, Solange Cavalcante, Jonathan E Golub, Richard E Chaisson, Valeria Saraceni","doi":"10.1097/QAD.0000000000004045","DOIUrl":"10.1097/QAD.0000000000004045","url":null,"abstract":"<p><strong>Objectives: </strong>Worldwide, adult men experience an excess burden of tuberculosis (TB) disease compared with women, but few studies have examined sex differences in TB among people with HIV. In this study, we aimed to investigate sex differences in TB infection and disease among people with HIV in Rio de Janeiro, Brazil.</p><p><strong>Design: </strong>Analysis of data from a randomized controlled trial and retrospective cohort study.</p><p><strong>Methods: </strong>We analyzed data from two studies conducted between 2005 and 2017. The THRio Study (2005-2012) evaluated increasing tuberculin skin testing (TST) and TB preventive therapy (TPT), and Universal ART in Rio study (UnivART; 2010-2017) was a virtual cohort study of people with HIV and TB with data from four national electronic registries.</p><p><strong>Results: </strong>Among 4606 people with HIV in THRio, 2992 (65.0%) had a TST placed and read, of whom 312 of 1865 (17%) males and 203 of 1127 (18%) females ( P = 0.37) had prevalent TB infection. TB disease incidence was higher among males compared with females overall [IRR 1.33, 95% confidence interval (95% CI) 1.04-1.69], among males compared with females who did not receive TPT [incidence rate ratios (IRR) 1.30, 95% CI 1.01-1.67], and among males compared with females on ART (IRR 1.64, 95% CI 1.17-2.29). Among 54 957 people with HIV in UnivART, TB disease incidence rates were higher among males than females overall (IRR 1.28, 95% CI 1.18-1.39), among males compared with females on ART (IRR 1.58, 95% CI 1.40-1.77), and among males compared with females not on ART (IRR 1.11, 95% CI 0.99-1.25).</p><p><strong>Conclusion: </strong>In this medium TB and HIV burden setting, TB disease incidence was higher among males than females with HIV, despite similar prevalence of TB infection.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"184-192"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142492845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}